Skip to main content Accessibility help
×
Home

Contents:

Information:

  • Access

Actions:

      • Send article to Kindle

        To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

        Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

        Find out more about the Kindle Personal Document Service.

        Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB)
        Available formats
        ×

        Send article to Dropbox

        To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

        Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB)
        Available formats
        ×

        Send article to Google Drive

        To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

        Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB)
        Available formats
        ×
Export citation

The author regrets to announce that the declarations of interest, listed in the above article (McCleery et al. 2015) contained an omission. The correct and complete version of the declaration of interest is given below.

M. F. Green and K. H. Nuechterlein are officers within MATRICS Assessment, Inc., the non-profit publisher of the MCCB, but do not receive any financial remuneration for their respective roles. M. F. Green has been a consultant to AbbVie, DSP, EnVivo, FORUM Pharmaceuticals, and Roche, and he is on the scientific advisory board of Mnemosyne. He has received research funds from Amgen (20130132). J. M. Gold receives royalty payments from The Brief Assessment of Cognition in Schizophrenia (BACS) and has been a consultant to Amgen, Hoffman-LaRoche, Lundback, and Pfizer. R. S. Kern has been an officer for MATRICS Assessment, Inc. and received financial compensation for his role within the non-profit organization. K. L. Subotnik has received research funding from Janssen Scientific Affairs, LLC, and Genentech, Inc., through grants to K. H. Nuechterlein and J. Ventura. K. L. Subotnik is a consultant to Otsuka America Pharmaceutical, Inc. J. Ventura has received funding from Genentech, Inc. (C4-150335). He has served as a consultant to Brain Plasticity, Inc., and Boehringer-Ingelheim GmbH. K. H. Nuechterlein has received research grants from Janssen Scientific Affairs (R092670SCH4005; RIS-NAP-4009), Genentech (ML28264), and Posit Science (BPI-1000-11) and has been a consultant to Otsuka, Janssen Scientific Affairs, and Genentech. R.S.E. Keefe currently or in the past 3 years has received investigator-initiated research funding support from the Department of Veteran's Affairs, Feinstein Institute for Medical Research, GlaxoSmithKline, National Institute of Mental Health, Novartis, Psychogenics, Research Foundation for Mental Hygiene, Inc., and the Singapore National Medical Research Council. He currently or in the past 3 years has received honoraria, served as a consultant, or advisory board member for Abbvie, Akebia, Amgen, Asubio, AviNeuro/ChemRar, BiolineRx, Biogen Idec, Biomarin, Boehringer-Ingelheim, Eli Lilly, EnVivo/FORUM, GW Pharmaceuticals, Janssen, Lundbeck, Merck, Minerva Neurosciences, Inc., Mitsubishi, Novartis, NY State Office of Mental Health, Otsuka, Pfizer, Reviva, Roche, Sanofi/Aventis, Shire, Sunovion, Takeda, Targacept, and the University of Texas South West Medical Center. R.S.E. Keefe receives royalties from the BACS testing battery, the MATRICS Battery (BACS Symbol Coding) and the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). He is also a shareholder in NeuroCog Trials, Inc. and Sengenix. Drs. McCleery, Hellemann, Baade, Mesholam-Gately, and Seidman declare they have no conflicts of interest.

Reference

McCleery, , Green, MF, Hellemann, GS, Baade, LE, Gold, JM, Keefe, RSE, Kern, RS, Mesholam-Gately, RI, Seidman, LJ, Subotnik, KL, Ventura, J, Nuechterlein, KH (2015). Latent structure of cognition in schizophrenia: A confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB). Psychological Medicine doi: 10.1017/S0033291715000562.